Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study).

Mohit K TuragamValay ParikhMuhammad R AfzalRakesh GopinathannairMadhav LavuArun KanmanthareddyJayasree PillarisettiMadhu ReddyDonita AtkinsSudharani BommanaMelissa JaegerCourtney JefferySanghamitra MohantyPasquale SantangeliJie ChengLuigi Di BiaseCalambur NarasimhanAndrea NataleDhanunjaya R Lakkireddy

Published in: Journal of cardiovascular electrophysiology (2017)

In WI patients rechallenged with DOACs, a significant proportion developed repeat MBE. LAAO devices seem reasonable in those patients who undergo major interventions to manage MBE with cautious and temporary continuation of DOAC.

Keyphrases

atrial fibrillation
direct oral anticoagulants
venous thromboembolism
end stage renal disease
oral anticoagulants
ejection fraction
newly diagnosed
chronic kidney disease
physical activity
prognostic factors
patient reported
brain injury
subarachnoid hemorrhage